Home > Name List By 4 > 4-aminohex-5-enoic acid China

CAS No 60643-86-9 , 4-aminohex-5-enoic acid Search by region : China

  • Name: 4-aminohex-5-enoic acid
  • Synonyms: Vigabatrinum [Latin]; Vigabatrine [French]; Vigabatrine;Sabril;4-aminohex-5-enoic acid; 4-aminohex-5-enoic acid; 4-Amino-5-hexenoic acid; gamma-Vinyl GABA;
  • CAS Registry Number:
  • Safety Statements: R36/37/38
  • Hazard Symbols: Xi: Irritant;
  • Molecular Weight: 129.15704
  • InchiKey: PJDFLNIOAUIZSL-UHFFFAOYSA-N
  • InChI: InChI=1S/C6H11NO2/c1-2-5(7)3-4-6(8)9/h2,5H,1,3-4,7H2,(H,8,9)
  • Risk Statements: S26;S36
  • Molecular Formula: C6H11NO2
  • Molecular Structure:CAS No:60643-86-9 4-aminohex-5-enoic acid

Select to

60643-86-9 Vigabatrin

  • Vigabatrin, also known as gamma-vinyl-GABA, is an antiepileptic drug that inhibits the breakdown of -aminobutyric acid (GABA) by acting as a suicide inhibitor of GABA transaminase (GABA-T). It is a structural analog of GABA, but does not bind to GABA...
  • FOB Price: USD150 - 1000 /
  • China Wuhan Sun-shine chemical Corporation Limited [Manufacturer, Trading Company]
  • Tel: 86--18312560332
  • Fax: --
  • Address: No.8 Rd, the Great Wall Park, DonghuHigh-Tech District wuhan,HubeiChina
Contact Supplier

60643-86-9 Vigabatrin

Contact Supplier

60643-86-9 Vigabatrin

  • China Inter-Chemical Ltd. [Manufacturers]
  • Tel: +86-(755)-82187211, 82192202
  • Fax: +86-(755)-82187212
  • Address: B-1108/1109, Tian An International Bldg., RenMin Nan Road, ShenZhen 518005, Shenzhen,GuangdongChina
Contact Supplier

Select to

References of 4-aminohex-5-enoic acid
Title: Vigabatrin
CAS Registry Number: 60643-86-9
CAS Name: 4-Amino-5-hexenoic acid
Synonyms: g-vinyl-g-aminobutyric acid; gamma-vinyl GABA; g-vinyl GABA; GVG
Manufacturers' Codes: MDL-71754; RMI-71754
Trademarks: Sabril (HMR)
Molecular Formula: C6H11NO2
Molecular Weight: 129.16
Percent Composition: C 55.79%, H 8.58%, N 10.84%, O 24.77%
Literature References: Irreversible inhibitor of g-aminobutyric acid transaminase, the enzyme responsible for the degradation of the neurotransmitter g-aminobutyric acid (GABA). Prepn: B. W. Metcalf, M. Jung, US 3960927 (1976 to Richardson-Merrell); and in vitro enzyme inactivation: B. Lippert et al., Eur. J. Biochem. 74, 441 (1977). Mechanism of action study: P. J. Schechter et al., Eur. J. Pharmacol. 45, 319 (1977). Anticonvulsant activity and toxicity studies: W. L?scher, Neuropharmacology 21, 803 (1982). HPLC determn in plasma and urine: J. A. Smithers et al., J. Chromatogr. 341, 232 (1985). The S(+)-enantiomer is the pharmacologically active form. Pharmacokinetics of enantiomers in humans: K. D. Haegele, P. J. Schechter, Clin. Pharmacol. Ther. 40, 581 (1986). Clinical studies in treatment resistant epilepsy: C. A. Tassinari et al., Arch. Neurol. 44, 907 (1987); T. R. Browne et al., Neurology 37, 184 (1987). Series of articles on clinical use in adult and childhood epilepsy: J. Child Neurol. 6, Suppl. 2, S3-S69 (1991). Reviews of early literature and mechanism of action: M. J. Iadarola, K. Gale, Mol. Cell. Biochem. 39, 305-330 (1981); of pharmacology and toxicology: E. J. Hammond, B. J. Wilder, Clin. Neuropharmacol. 8, 1-12 (1985). Review: S. M. Grant, R. C. Heel, Drugs 41, 889-926 (1991).
Properties: Crystals from acetone/water, mp 209°. Freely sol in water. LD50 i.p. in mice: >2500 mg/kg (L?scher).
Melting point: mp 209°
Toxicity data: LD50 i.p. in mice: >2500 mg/kg (L?scher)
Therap-Cat: Anticonvulsant.
Keywords: Anticonvulsant.